Results 191 to 200 of about 4,021,724 (320)

Progress report of a cross-organ and biomarker-based basket-type clinical trial: BELIEVE Trial. [PDF]

Cancer Sci
Ando Y, Shimoi T, Sunami K, Okita N, Nakamura K, Shibata T, Fujiwara Y, Yamamoto N.   +7 more
europepmc   +1 more source

Digital Microfluidics in Newborn Screening for Mucopolysaccharidoses: A Progress Report. [PDF]

Int J Neonatal Screen, 2020
Washburn J, Millington DS.
europepmc   +1 more source

Ethiopian paediatric oncology registry progress report: documentation practice improvements at tertiary care centre in Addis Ababa, Ethiopia. [PDF]

Arch Dis Child, 2021
Levy S, Fentie AM, Buhlinger K, Clark SM, Korones DN, Miller V, Alexander TB, Weitzman S, Bekele W, Broas J, Shad A, Roberts M, Chargualaf M, Fufa D, Hailu T, Yimer MA, Mustefa M, Said Gidey AM, Dinkiye AM, Adam H, Hailu D, Muluneh B.   +21 more
europepmc   +1 more source

Progress progress report 1

Activity report for the first reporting period of the project.
openaire   +1 more source

Utilization of kinetic isotope effects for the concentration of tritium. 1997 annual progress report

, 1997
Gilbert M. Brown, Thomas J. Meyer
openalex   +2 more sources

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Final progress report (+ other interim progress reports)

Final progress report (+ other interim progress reports). The interim progress reports will be delivered at regular 6-monthly intervals.
openaire   +1 more source

METALS AND CERAMICS DIVISION ANNUAL PROGRESS REPORT FOR PERIOD ENDING JUNE 30, 1971.

, 1971
S. Peterson
openalex   +2 more sources

Youth Taskforce : progress report : summer 2009 [PDF]

, 2009

core  

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source